Advertisement
Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting Co., Ltd (3347.HK) Stock Competitors & Peer Comparison

See (3347.HK) competitors and their performances in Stock Market.

3347.HKHKSE
HealthcareBiotechnology
HK$33.98
HK$1.10(3.35%)
Hong Kong Market opens in 40h 50m
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
3347.HKHK$33.98+3.35%41.2B34.78HK$0.98+0.43%
4332.HKHK$1,850.00+0.00%998.5B16.70HK$110.75N/A
6160.HKHK$165.90-0.66%223.8B75.00HK$2.21N/A
2269.HKHK$33.04-0.18%136.9B25.85HK$1.28N/A
1801.HKHK$75.15-1.25%130.4B138.19HK$0.54N/A
6990.HKHK$418.00+1.31%97.5B-207.23-HK$2.02N/A
9926.HKHK$83.30-2.52%76.6B-62.10-HK$1.34N/A
6821.HKHK$111.30+2.58%40.2B36.49HK$3.05+1.34%
1530.HKHK$15.91-0.93%39.8B4.14HK$3.84+1.57%
2696.HKHK$55.50-6.49%30.2B22.37HK$2.48N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

3347.HK vs 4332.HK Comparison June 2026

3347.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 3347.HK stands at 41.2B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 3347.HK is priced at HK$33.98, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

3347.HK currently has a P/E ratio of 34.78, whereas 4332.HK's P/E ratio is 16.70. In terms of profitability, 3347.HK's ROE is +0.04%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 3347.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 3347.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions